Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 1
2010 1
2011 2
2013 1
2014 3
2015 3
2016 1
2017 2
2018 4
2019 2
2020 3
2021 5
2022 3
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
New Landscape: Physician Compensation.
Thomas CA, Hirschorn AM, Tomkins JE, Birch WE, Bosserman LD, Patt DA, Patel DR, Diaz M, Marsland TA, Klix MM, Balaban EP, Blanchard EM, Franklin GE, Seth R, Norden A. Thomas CA, et al. Among authors: patt da. JCO Oncol Pract. 2021 Apr;17(4):186-189. doi: 10.1200/OP.20.00788. Epub 2020 Dec 22. JCO Oncol Pract. 2021. PMID: 33351676 No abstract available.
The Road of Mentorship.
Cooke KJ, Patt DA, Prabhu RS. Cooke KJ, et al. Among authors: patt da. Am Soc Clin Oncol Educ Book. 2017;37:788-792. doi: 10.1200/EDBK_175193. Am Soc Clin Oncol Educ Book. 2017. PMID: 28561670 Free article.
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Martín M, et al. J Clin Oncol. 2024 Jun 20;42(18):2149-2160. doi: 10.1200/JCO.23.01500. Epub 2024 Mar 27. J Clin Oncol. 2024. PMID: 38537155 Free PMC article. Clinical Trial.
34 results